Skip to main content
. 2021 Jun 15;79(3):497–508. doi: 10.1007/s12013-021-00988-9

Table 2.

Current development of LysoPS analog

Compound Target EC50 (nM)
LPS1 LPS2 LPS3 Mast cell degranulation Refs.
graphic file with name 12013_2021_988_Taba_HTML.gif Pan-agonist 230–550 20–28 300–520 150 [44, 70, 71, 75, 76]
graphic file with name 12013_2021_988_Tabb_HTML.gif LPS1, LPS2 360 93 Inactive n.t. [70]
graphic file with name 12013_2021_988_Tabc_HTML.gif LPS2, Mast cell >1 μM 25–30 Inactive 200 [70, 71, 76]
graphic file with name 12013_2021_988_Tabd_HTML.gif LPS1 37 >1 μM Inactive n.t. [75]
graphic file with name 12013_2021_988_Tabe_HTML.gif LPS1 5 >3 μM Inactive n.t. [74]
graphic file with name 12013_2021_988_Tabf_HTML.gif LPS2 Inactive 6.7 Inactive n.t. [75]
graphic file with name 12013_2021_988_Tabg_HTML.gif LPS2 >1 μM 3.3 >1 μM n.t. [71]
graphic file with name 12013_2021_988_Tabh_HTML.gif LPS3 Inactive >1 μM 31 n.t. [71]
graphic file with name 12013_2021_988_Tabi_HTML.gif Mast cell Inactive >1 μM >3 μM 10 [70, 76]
graphic file with name 12013_2021_988_Tabj_HTML.gif Mast cell Inactive Inactive inactive 3 [76]
graphic file with name 12013_2021_988_Tabk_HTML.gif LPS2, Mast cell >1 μM 1.7 >1 μM 300 [71, 76]